Atlas Venture Life Science Advisors, LLC Dyne Therapeutics, Inc. Transaction History
Atlas Venture Life Science Advisors, LLC
- $443 Million
- Q3 2025
A detailed history of Atlas Venture Life Science Advisors, LLC transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Atlas Venture Life Science Advisors, LLC holds 9,130,465 shares of DYN stock, worth $171 Million. This represents 26.07% of its overall portfolio holdings.
Number of Shares
9,130,465
Previous 9,130,465
-0.0%
Holding current value
$171 Million
Previous $86.9 Million
32.88%
% of portfolio
26.07%
Previous 19.12%
Shares
6 transactions
Others Institutions Holding DYN
# of Institutions
220Shares Held
130MCall Options Held
36.5KPut Options Held
138K-
Vanguard Group Inc Valley Forge, PA9.76MShares$182 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA9.71MShares$181 Million2.02% of portfolio
-
Janus Henderson Group PLC London, X09.44MShares$176 Million0.05% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$138 Million0.01% of portfolio
-
Fcpm Iii Services B.V. Naarden, P75.46MShares$102 Million14.09% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $967M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...